Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy.
OBJECTIVE
Since the advent of highly active antiretroviral therapy (HAART), the incidence of Kaposi's sarcoma (KS) among AIDS patients has declined both nationwide and in King County, Washington. We sought to compare clinical parameters of patients diagnosed with KS in the pre-HAART (1990 to 1996) and HAART (1997 to 2002) eras.


METHODS
We used patient data abstracted from the Adult/Adolescent Spectrum of HIV-Related Diseases study of Public Health-Seattle and King County.


RESULTS
Patients diagnosed with KS in the HAART era (n = 40) were significantly more likely (P < .05) than pre-HAART-era KS patients (n = 366) to be diagnosed with alcohol problems (43% v 18%), noninjection drug use (45% v 18%), injection drug use (25% v 10%), psychosis (25% v 13%), and hypertension (13% v 2%). Although median CD4(+) count and HIV-1 viral load at the time of KS diagnosis were not significantly different between the two groups, significantly fewer (P < .01) HAART-era KS patients developed opportunistic illnesses (OIs) during their follow-up. The risk of dying among KS patients diagnosed in the HAART era is significantly lower (P < .01) than for KS patients diagnosed in the pre-HAART era (hazard ratio, 0.24).


CONCLUSIONS
Although HAART-era KS patients in King County were as likely to have a depleted CD4(+) cell count and high HIV-1 viral loads at the time of KS diagnosis as pre-HAART KS patients, they survived longer and fewer of them were diagnosed with other OIs. They also had an increased prevalence of substance abuse and mental illness, contributing to a dynamic and changing KS clinical profile.
Gallafent
James H
JH
University of Washington, School of Medicine, Department of Epidemiology, Seattle, WA, USA.
Buskin
Susan E
SE
De Turk
Peter B
PB
Aboulafia
David M
DM
D017088:AIDS-Related Opportunistic Infections; D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000293:Adolescent; D000328:Adult; D000437:Alcoholism / Q000453:epidemiology; D023241:Antiretroviral Therapy, Highly Active; D015704:CD4 Antigens / Q000032:analysis; D015897:Comorbidity; D005260:Female; D015497:HIV-1 / Q000302:isolation & purification; D006801:Humans; D015994:Incidence; D008297:Male; D001523:Mental Disorders / Q000453:epidemiology; D008875:Middle Aged; D012514:Sarcoma, Kaposi / Q000453:epidemiology*; D019966:Substance-Related Disorders / Q000453:epidemiology; D016019:Survival Analysis; D019562:Viral Load
D015704:CD4 Antigens